Cover Image
市場調查報告書

亞太地區非何杰金氏淋巴瘤(NHL)治療藥市場:復發性/難治性之相當有前途的新技術

Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting

出版商 GBI Research 商品編碼 312872
出版日期 內容資訊 英文 96 Pages
訂單完成後即時交付
價格
Back to Top
亞太地區非何杰金氏淋巴瘤(NHL)治療藥市場:復發性/難治性之相當有前途的新技術 Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting
出版日期: 2014年09月15日 內容資訊: 英文 96 Pages
簡介

亞太地區非何杰金氏淋巴瘤(NHL)治療藥市場,預計從2013年的11億美元,至2020年到規模擴大17億美元,以CAGR6.6%成長。

本報告提供亞太地區非何杰金氏淋巴瘤(NHL)治療藥市場相關調查分析、市場概要、上市產品、開發中產品、市場預測、交易和策略性整合等相關的系統性資訊。

第1章 目錄

第2章 簡介

  • 症狀
  • 病因
  • 病理學
  • 診斷
  • 分類
  • 流行病學
  • 預後與疾病的重病度
  • 治療的選項

第3章 上市產品

  • 治療情形
  • 有效性和安全性比較(上市產品)

第4章 開發中產品

  • 開發平台全體
  • 開發平台分析:各分子類型
  • 開發平台分析:各作用機制
  • 臨床試驗
  • 開發平台的有前途藥物的候補
    • Idelalisib (GS-1101)
    • Imbruvica (Ibrutinib)
    • Gazyva (Obinutuzumab)
    • Revlimid (lenalidomide)
    • Afinitor (everolimus)
  • 開發中產品的熱圖

第5章 市場預測

  • 各地區市場
    • 亞太地區
    • 印度
    • 澳洲
    • 中國
    • 日本
  • 推動市場要素與阻礙

第6章 與交易策略性整合

  • 主要的共同開發交易
  • 主要的許可證交易

第7章 附錄

圖表

目錄

Summary

GBI Research, the leading business intelligence provider, has released its latest research, 'Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting', which provides in-depth insights into the indication. It gives an estimation of market size for 2013 along with forecasts until 2020 for the Asia-Pacific (APAC) region, which comprises Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Non-Hodgkin Lymphoma (NHL). The market in the APAC region was worth an estimated $1.1 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.6% to $1.7 billion in 2020. The expected launches of promising drugs, including novel protein kinase inhibitors and next-generation monoclonal antibodies, as well as the continued use of the current blockbuster, Rituxan/Mabthera, will be the key growth drivers. The launch of premium-priced novel glycol-engineered antibody; obinutuzumab; kinase inhibitors including idelalisib and ibrutinib; and the mTOR inhibitor everolimus are also expected to have a significant impact, as is the anticipated approval of immunomodulatory agent Revlimid as a maintenance setting. An increasingly aging population and a year-on-year increase in the number of incident cases will provide an additional boost. However, the recent implementation of a price ceiling on essential drugs in India; anticipated pricing restrictions in China; and low access, penetration and price erosion due to generic dominance, especially in India, stand to curtail the APAC NHL market.

Scope

The report analyzes treatment usage patterns, market characterization, the pipeline, and key licensing and co-development deals in the four APAC markets of Australia, China, India and Japan. It includes -

  • A brief introduction to NHL, including the disease's pathogenesis, etiology, diagnosis and treatment algorithms
  • In-depth analysis of currently marketed drugs for NHL, examining their safety, efficacy, treatment patterns and strengths/weaknesses and including a heat map that compares the drugs in terms of safety and efficacy
  • A comprehensive review of the pipeline for NHL, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period; the pipeline is analyzed on the basis of Phase distribution, molecule type, program type, mechanism of action and molecular target
  • Additional in-depth analysis of pipeline drug clinical trials by Phase, trial size, trial duration and program failure rate for each molecule type
  • Multi-scenario forecast data of the market to 2020, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets
  • Discussion of the drivers of and barriers to market growth
  • In-depth analysis of all licensing and co-development deals that have occurred in the NHL market since 2006

Reasons to buy

The report will enhance your decision-making capability by allowing you to -

  • Understand the NHL pipeline and the factors that indicate that it is becoming more innovative
  • Examine detailed profiles of promising pipeline products and gain an insight into how they are likely to compete in the market and who their main competitors will be
  • Follow the trends in NHL clinical trial size and duration in relation to industry averages and assess the potential risk of future developmental programs according to mechanism of action by considering the recorded clinical trial failure rates
  • Observe the potential growth patterns expected for the NHL market over the forecast period, identify which countries are expected to make the biggest contribution to this growth, and devise a more effective country - strategy through an understanding of key drivers and barriers in the NHL market
  • Accelerate and strengthen your market position by identifying key companies for strategic partnerships

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Symptoms
  • 2.2. Etiology
  • 2.3. Pathophysiology
  • 2.4. Diagnosis
    • 2.4.1. Biopsy
    • 2.4.2. Laboratory molecular tests
    • 2.4.3. Imaging tests
  • 2.5. Classification
    • 2.5.1. B-Cell lymphomas
    • 2.5.2. T-Cell Lymphomas
  • 2.6. Epidemiology
  • 2.7. Prognosis and Disease Staging
    • 2.7.1. Staging
  • 2.8. Treatment Options
    • 2.8.1. Surgery and Radiation Therapy
    • 2.8.2. Stem Cell Transplantation
    • 2.8.3. Pharmacological
    • 2.8.4. Treatment Algorithms and Prescribing Habits

3. Marketed Products

  • 3.1. Therapeutic Landscape
    • 3.1.1. Immunotherapies
    • 3.1.2. Targeted Therapies
    • 3.1.3. Chemo-Regimens
  • 3.2. Comparative Efficacy and Safety (Marketed Products)

4. Pipeline Products

  • 4.1. Overall Pipeline
  • 4.2. Pipeline Analysis by Molecule Type
  • 4.3. Pipeline Analysis by Mechanism of Action
  • 4.4. Clinical Trials
    • 4.4.1. Failure Rate
    • 4.4.2. Patient Enrollment and Clinical Trial Size
    • 4.4.3. Duration
  • 4.5. Promising Drug Candidates in the Pipeline
    • 4.5.1. Idelalisib (GS-1101) - Gilead Sciences
    • 4.5.2. Imbruvica (Ibrutinib) - Pharmacyclics/Janssen Biotech
    • 4.5.3. Gazyva (Obinutuzumab) - Roche
    • 4.5.4. Revlimid (lenalidomide) - Celgene
    • 4.5.5. Afinitor (everolimus) - Novartis
  • 4.6. Heat Map of Safety and Efficacy and Product Competitiveness Framework for Non-Hodgkin Lymphoma Pipeline

5. Market Forecast to 2020

  • 5.1. Geographical Markets
    • 5.1.1. APAC Market
    • 5.1.2. India
    • 5.1.3. Australia
    • 5.1.4. China
    • 5.1.5. Japan
  • 5.2. Drivers and Barriers for the Disease Market
    • 5.2.1. Drivers
    • 5.2.2. Barriers

6. Deals and Strategic Consolidations

  • 6.1. Major Co-development Deals
    • 6.1.1. Roche Signs an Agreement with GlycArt and Genentech
    • 6.1.2. Cell Therapeutics Enters Agreement with Bayer
    • 6.1.3. Chugai Enters Co-development Agreement with Nippon Shinyaku for GA101
    • 6.1.4. GlaxoSmithKline Enters Co-development Agreement with Genmab
    • 6.1.5. Biogen Idec Enters Co-development Agreement with Genentech
    • 6.1.6. Seattle Genetics Enters Co-development Agreement with Millennium
  • 6.2. Major Licensing Deals
    • 6.2.1. Spectrum Enters Licensing Agreement with Bayer for Zevalin
    • 6.2.2. Janssen Biotech Enters Licensing Agreement with Pharmacyclics for PCI-32765
    • 6.2.3. Lundbeck Enters Licensing Agreement with Cephalon
    • 6.2.4. TG Therapeutics Enters Licensing Agreement with Ildong for Ublituximab
    • 6.2.5. Provenance Enters Licensing Agreement with Merck Serono
    • 6.2.6. Cephalon Enters Licensing Agreement with SymBio
    • 6.2.7. Genentech Enters Licensing Agreement with Seattle Genetics

7. Appendix

  • 7.1. Market Definitions
  • 7.2. Abbreviations
  • 7.3. Bibliography
  • 7.4. Pipeline Tables
    • 7.4.1. Discovery
    • 7.4.2. Preclinical
    • 7.4.3. Investigational New Drug-Filed
    • 7.4.4. Phase I
    • 7.4.5. Phase II
    • 7.4.6. Phase III
  • 7.5. Market Forecasts to 2020
    • 7.5.1. Asia-Pacific
    • 7.5.2. India
    • 7.5.3. Australia
    • 7.5.4. China
    • 7.5.5. Japan
  • 7.6. Research Methodology
    • 7.6.1. Coverage
    • 7.6.2. Secondary Research
    • 7.6.3. Primary Research
    • 7.6.4. Therapeutic Landscape
    • 7.6.5. Geographical Landscape
    • 7.6.6. Pipeline Analysis
  • 7.7. Expert Panel Validation
  • 7.8. Contact Us
  • 7.9. Disclaimer

List of Tables

  • Table 1: Non-Hodgkin Lymphoma Therapeutics, Most Common Chromosomal Aberrations Associated With NHL
  • Table 2: Non-Hodgkin Lymphoma Therapeutics, IWF Classification of Lymphoproliferative Diseases
  • Table 3: Non-Hodgkin Lymphoma Market, Classification of Non-Hodgkin Lymphoma
  • Table 4: Non-Hodgkin Lymphoma Market, IPI Good and Poor Prognostic Factors
  • Table 5: Non-Hodgkin Lymphoma Market, Ann Arbor Staging System for Lymphoma
  • Table 6: Non-Hodgkin Lymphoma Market, Commonly Used Chemo-Regimens
  • Table 7: Non-Hodgkin Lymphoma Market, Common Symptoms of Non-Hodgkin Lymphoma
  • Table 8: Non-Hodgkin Lymphoma Market, Endpoints of Various Chemotherapeutic Regimens (%)
  • Table 9: Non-Hodgkin Lymphoma Market, Efficacy Comparison of R-CHOP vs. CHOP
  • Table 10: Non-Hodgkin Lymphoma Market, Efficacy Comparison of CVP vs R-CVP
  • Table 11: Non-Hodgkin Lymphoma Market, Global, Average Clinical Trial Duration (Months)
  • Table 12: Non-Hodgkin Lymphoma Market, Global, Deals and Strategic Consolidations, 2006-2014
  • Table 13: Non-Hodgkin Lymphoma Market, Global, Pharmaceutical Pipeline (Discovery), 2014
  • Table 14: Non-Hodgkin Lymphoma Market, Global, Pharmaceutical Pipeline (Preclinical), 2014
  • Table 15: Non-Hodgkin Lymphoma Market, Global, Pharmaceutical Pipeline (IND-filed), 2014
  • Table 16: Non-Hodgkin Lymphoma Market, Global, Pharmaceutical Pipeline (Phase I), 2014
  • Table 17: Non-Hodgkin Lymphoma Market, Global, Pharmaceutical Pipeline (Phase II), 2014
  • Table 18: Non-Hodgkin Lymphoma Market, Global, Pharmaceutical Pipeline (Phase III), 2014
  • Table 19: Non-Hodgkin Lymphoma Market, Asia-Pacific, Market Forecast, 2013-2020
  • Table 20: Non-Hodgkin Lymphoma Market, India, Market Forecast, 2013-2020
  • Table 21: Non-Hodgkin Lymphoma Market, Australia, Market Forecast, 2013-2020
  • Table 22: Non-Hodgkin Lymphoma Market, China, Market Forecast, 2013-2020
  • Table 23: Non-Hodgkin Lymphoma Market, Japan, Market Forecast, 2013-2020

List of Figures

  • Figure 1: Non-Hodgkin Lymphoma Market, Asia-Pacific, Distribution of Prevalence Population, 2013-2020
  • Figure 2: Non-Hodgkin Lymphoma Market, Treatment Algorithm for Indolent Non-Hodgkin Lymphoma, 2014
  • Figure 3: Non-Hodgkin Lymphoma Market, Treatment Algorithm for Aggresive Non-Hodgkin Lymphoma, 2014
  • Figure 4: Non-Hodgkin Lymphoma Market, Global, Rituxan, Annual Sales ($bn), 2006-2013
  • Figure 5: Non-Hodgkin Lymphoma Market, Global, Adcetris, Annual Sales ($m), 2011-2013
  • Figure 6: Non-Hodgkin Lymphoma Market, Global, Velcade, Annual Sales ($bn), 2007-2013
  • Figure 7: Non-Hodgkin Lymphoma Market, Global, Istodax, Annual Sales ($m), 2010-2013
  • Figure 8: Non-Hodgkin Lymphoma Market, Global, Comparative Safety and Efficacy of Marketed Products (Heat Map), 2014
  • Figure 9: Non-Hodgkin Lymphoma Market, Global, Pipeline by Stage of Development, Program Type and Route of Administration, 2014
  • Figure 10: Non-Hodgkin Lymphoma Market, Global, Pipeline by Molecule Type and Stage of Development, 2014
  • Figure 11: Non-Hodgkin Lymphoma Market, Global, Pipeline by Mechanism of Action, 2014
  • Figure 12: Non-Hodgkin Lymphoma, Global, Pipeline by Mechanism of Action, Molecule Type and Stage of Development (Number), 2014
  • Figure 13: Non-Hodgkin Lymphoma Market, Global, Clinical Trial Failure Rate (%), 2014
  • Figure 14: Non-Hodgkin Lymphoma Market, Global, Clinical Trial Size (Participants), 2014
  • Figure 15: Non-Hodgkin Lymphoma Market, Global, Pipeline Clinical Trial Duration (Months), 2014
  • Figure 16: Non-Hodgkin Lymphoma Market, Global, Comparative Safety and Efficacy of Pipeline Products (Heat Map), 2014
  • Figure 17: Non-Hodgkin Lymphoma Market, Asia-Pacific, Market Size, 2013-2020
  • Figure 18: Non-Hodgkin Lymphoma Market, India, Treatment Usage Pattern ('000), 2013-2020
  • Figure 19: Non-Hodgkin Lymphoma Market, India, Annual Cost of Therapy ($), 2013-2020
  • Figure 20: Non-Hodgkin Lymphoma Market, India, Market Size ($m), 2013-2020
  • Figure 21: Non-Hodgkin Lymphoma Market, Australia, Treatment Usage Pattern ('000), 2013-2020
  • Figure 22: Non-Hodgkin Lymphoma Market, Australia, Annual Cost of Therapy ($'000), 2013-2020
  • Figure 23: Non-Hodgkin Lymphoma Market, Australia, Market Size ($m), 2013-2020
  • Figure 24: Non-Hodgkin Lymphoma Market, China, Treatment Usage Pattern ('000), 2013-2020
  • Figure 25: Non-Hodgkin Lymphoma Market, China, Annual Cost of Therapy, 2013-2020
  • Figure 26: Non-Hodgkin Lymphoma Market, China, Market Size ($m), 2013-2020
  • Figure 27: Non-Hodgkin Lymphoma Market, Japan, Treatment Usage Pattern ('000), 2013-2020
  • Figure 28: Non-Hodgkin Lymphoma Market, Japan, Annual Cost of Therapy ($'000), 2013-2020
  • Figure 29: Non-Hodgkin Lymphoma Market, Japan, Market Size ($m), 2013-2020
  • Figure 30: Non-Hodgkin Lymphoma Market, Global Deals by Value, Year and Stage of Development, 2006-2014
  • Figure 31: Non-Hodgkin Lymphoma Market, Global, Deals by Phase, Molecule Type and Mechanism of Action, 2006-2014
  • Figure 32: Non-Hodgkin Lymphoma Market, Global, Co-development Deals by Geography, 2006-2014
  • Figure 33: Non-Hodgkin Lymphoma Market, Global, Licensing Deals by Geography, 2006-2014
  • Figure 34: GBI Research Market Forecasting Model
Back to Top